Danaher Corporation (DHR)vsExagen Inc (XGN)
DHR
Danaher Corporation
$187.15
-1.55%
HEALTHCARE · Cap: $134.43B
XGN
Exagen Inc
$2.88
+5.11%
HEALTHCARE · Cap: $65.91M
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 36803% more annual revenue ($24.57B vs $66.58M). DHR leads profitability with a 14.7% profit margin vs -30.0%. DHR earns a higher WallStSmart Score of 60/100 (C).
DHR
Buy60
out of 100
Grade: C
XGN
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-38.6%
Fair Value
$135.07
Current Price
$187.15
$52.08 premium
Intrinsic value data unavailable for XGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.2%
Generating 1.7B in free cash flow
Revenue surging 21.8% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
4.6% revenue growth
ROE of 7.0% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -147.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bull Case : XGN
The strongest argument for XGN centers on Revenue Growth. Revenue growth of 21.8% demonstrates continued momentum.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : XGN
The primary concerns for XGN are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
DHR profiles as a value stock while XGN is a growth play — different risk/reward profiles.
XGN carries more volatility with a beta of 1.91 — expect wider price swings.
XGN is growing revenue faster at 21.8% — sustainability is the question.
DHR generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (60/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Exagen Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name in the United States. The company is headquartered in Vista, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?